Fate Therapeutics' (FATE) "Neutral" Rating Reiterated at Wedbush
Wedbush reiterated their neutral rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a report issued on Tuesday, Benzinga reports. The firm currently has a $7.00 price objective on the biopharmaceutical company’s stock. Other analysts also recently issued reports about the stock. HC Wainwright reaffirmed a neutral rating and issued a $7.00 price […]